Document:

<PAGE>
                                                                     Exhibit 4.2
R- 1                                                                $325,000,000

                     INTERNATIONAL LEASE FINANCE CORPORATION

                          2.95% NOTES DUE MAY 23, 2006

THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER
REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE OF A
DEPOSITARY. THIS GLOBAL SECURITY IS EXCHANGEABLE FOR NOTES REGISTERED IN THE
NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS NOTE (OTHER
THAN A TRANSFER OF THIS NOTE AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE
DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER
NOMINEE OF THE DEPOSITARY) MAY BE REGISTERED EXCEPT IN SUCH LIMITED
CIRCUMSTANCES.

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY (55 WATER STREET, NEW YORK, NEW YORK) TO THE ISSUER OR
ITS AGENT FOR THE REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY
CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS
REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY AND
ANY PAYMENT IS MADE TO CEDE & CO., ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR
VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER
HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

PRINCIPAL AMOUNT: Three Hundred Twenty Five Million Dollars ($325,000,000)

MATURITY DATE: May 23, 2006

DATED DATE: May 23, 2003

INTEREST RATE: 2.95% per annum

CUSIP: 459745 FH3

ISIN: US459745FH38

COMMON CODE: 16946419

INTEREST PAYMENT DATES: May 23 and November 23, commencing November 23, 2003

REGULAR RECORD DATES: The date 15 calendar days prior to each interest payment
date
<PAGE>
            INTERNATIONAL LEASE FINANCE CORPORATION, a California corporation
(the "Company"), for value received, hereby promises to pay to Cede & Co., or
registered assigns, the principal amount set forth on the face hereof on the
Maturity Date set forth on the face hereof, and to pay interest thereon, at the
interest rate set forth on the face hereof, from the dated date hereof or from
the most recent Interest Payment Date to which interest has been paid or duly
provided for, semi-annually on the Interest Payment Dates set forth on the face
hereof, until the principal hereof has been paid or made available for payment.
The interest so payable, and punctually paid or provided for, on any Interest
Payment Date will, as provided in the Indenture (as hereinafter defined), be
paid to the Person in whose name this Note (or one or more Predecessor
Securities) is registered at the close of business on the Regular Record Date
for such interest as set forth on the face hereof (whether or not a Business
Day), as the case may be, next preceding such Interest Payment Date; provided,
however, interest payable on the Maturity Date hereof will be payable to the
Person to whom the principal hereof shall be payable. Any such interest which is
payable, but is not punctually paid or duly provided for on any Interest Payment
Date, shall forthwith cease to be payable to the registered Holder on such
Regular Record Date, and may be paid to the Person in whose name this Note (or
one or more Predecessor Securities) is registered at the close of business on a
Special Record Date for the payment of such defaulted interest to be fixed by
the Trustee, notice whereof shall be given to the Holder of this Note at least
10 days prior to such Special Record Date, or may be paid at any time in any
other lawful manner, all as more fully provided in the Indenture. Payment of the
principal of and interest on this Note will be made at the office of the Trustee
in the Borough of Manhattan, City of New York, State of New York, in such coin
or currency of the United States of America as at the time of payment is legal
tender for payment of public and private debts; provided, however, that payment
of interest on any Interest Payment Date (other than on the Maturity Date) may
be made at the option of the Company by check mailed to the address of the
Person entitled thereto as such address shall appear in the Security Register.

            This Note is one of a duly authorized issue of Securities
(hereinafter called the "Securities") of the Company, issued and to be issued
under an Indenture dated as of November 1, 2000 (herein called the "Indenture")
between the Company and The Bank of New York, as Trustee (herein called the
"Trustee", which term includes any successor trustee under the Indenture), as
amended, to which Indenture and all indentures supplemental thereto reference is
hereby made for a statement of the respective rights thereunder of the Company,
the Trustee and the Holders of the Securities, and the terms upon which the
Securities are, and are to be, authenticated and delivered. All terms used in
this Note which are defined in the Indenture shall have the meanings assigned to
them in the Indenture.

            After the completion of the issuance for which this Note is a part,
the Company may, from time to time, reopen such issuance and issue additional
Securities with the same terms (including maturity and interest payment terms)
as this Note. After such additional Securities are issued, they will be fungible
with this Note.

            This Note is one of the series of Securities designated as set forth
on the face hereof. The Notes may not be redeemed prior to maturity. The Notes
will not have a sinking fund.

            If an Event of Default with respect to the Notes shall occur and be
continuing, the Trustee or the Holders of not less than 25% in principal amount
of the Outstanding Notes may declare the principal of all the Notes due and
payable in the manner and with the effect provided in the Indenture.

            The Indenture permits, with certain exceptions as therein provided,
the amendment thereof and the modification of the rights and obligations of the
Company and the rights of the Holders of the Securities of each series to be
affected under the Indenture at any time by the Company and the Trustee with the
consent of the Holders of a majority in aggregate principal amount of the
Securities at the time Outstanding, of each series affected thereby. The
Indenture also contains provisions permitting the Holders of specified
percentages in aggregate principal amount of the Securities of each series at
the time Outstanding, on behalf of the Holders of all Securities of each series,
to waive compliance by the Company with certain provisions of the Indenture and
certain past defaults under the Indenture and their consequences. Any such
consent or waiver by the Holder of this Note shall be conclusive and binding
upon such Holder and upon all future Holders of this Note and of any Note issued
upon the registration of transfer hereof or in exchange herefor or in lieu
hereof whether or not notation of such consent or waiver is made upon this Note.
<PAGE>
            No reference herein to the Indenture and no provision of this Note
or of the Indenture shall alter or impair the obligation of the Company, which
is absolute and unconditional, to pay the principal of and interest on this Note
at the time, place and rate, and in the coin or currency, herein prescribed.

            As provided in the Indenture and subject to certain limitations
therein set forth, the transfer of this Note may be registered on the Security
Register of the Company upon surrender of this Note for registration of transfer
at the office of the Trustee in the Borough of Manhattan, City of New York,
State of New York, duly endorsed by, or accompanied by a written instrument of
transfer in form satisfactory to the Company and Security Registrar duly
executed by, the Holder hereof or by his attorney duly authorized in writing,
and thereupon one or more new Notes of authorized denominations and for the same
aggregate principal amount, will be issued to the designated transferee or
transferees.

            The Notes are issuable only in registered form without coupons in
denominations of $1,000 or any amount in excess thereof which is an integral
multiple of $1,000. As provided in the Indenture and subject to certain
limitations therein set forth, the Notes are exchangeable for a like aggregate
principal amount of Notes, as requested by the Holder surrendering the same.

            No service charge will be made for any such registration of transfer
or exchange, but the Company may require payment of a sum sufficient to cover
any tax or other governmental charge payable in connection therewith.

            Prior to due presentment of this Note for registration of transfer,
the Company, the Trustee and any agent of the Company or the Trustee may treat
the Person in whose name this Note is registered as the owner hereof for all
purposes, whether or not this Note be overdue, and neither the Company, the
Trustee nor any such agent shall be affected by notice to the contrary.

                                       2
<PAGE>
            IN WITNESS WHEREOF, the Company has caused this instrument to be
duly executed under its corporate seal as of the Dated Date set forth on the
face hereof.

                                    INTERNATIONAL LEASE FINANCE CORPORATION

[Seal]

                                    By:
                                        ----------------------------------------
                                        Chairman of the Board

                                        ----------------------------------------
                                        President

Attest:

----------------------------------
           Secretary

            Unless the certificate of authentication hereon has been executed by
The Bank of New York, the Trustee under the Indenture, or its successor
thereunder, by the manual signature of one of its authorized signatories or
authorized Authenticating Agents, this Note shall not be entitled to any
benefits under the Indenture, or be valid or obligatory for any purpose.

                          CERTIFICATE OF AUTHENTICATION

            This is one of the Securities of the series designated herein
referred to in the within-mentioned Indenture.

Date of Registration:

                                              THE BANK OF NEW YORK, as Trustee

                                              By
                                                 -------------------------------
                                                 Authorized Signatory

                                       3
<PAGE>
                              [FORM OF ASSIGNMENT]

                                  ABBREVIATIONS

            The following abbreviations, when used in the inscription on the
face of this instrument, shall be construed as though they were written out in
full according to applicable laws or regulations.

         TEN COM --        as tenants in common
         TEN ENT --        as tenants by the entireties
         JT TEN  --        as joint tenants with right of survivorship and not
                           as tenants in common

UNIF GIFT MIN ACT -- __________________ Custodian ___________________
                           (Cust)                      (Minor)

under Uniform Gifts to Minors Act _____________________________
                                            (State)

     Additional abbreviations may also be used though not in the above list.

            FOR VALUE RECEIVED, the undersigned hereby sell(s), assign(s) and
transfer(s) unto

Please insert Social Security or Other
Identifying Number of Assignee
                                            ------------------------------------

PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS INCLUDING POSTAL ZIP CODE OF ASSIGNEE

------------------------------------------------------

------------------------------------------------------

the within Note and all rights thereunder, hereby irrevocably constituting and
appointing

_____________________________________________________ Attorney to transfer said
Note on the books of the Company, with full power of substitution in the
premises.

Dated:
       --------------------------------

                                      ------------------------------------------

                                      ------------------------------------------
                                      Notice:  The signature to this assignment
                                               must correspond with the name as
                                               written on the face of the within
                                               instrument in every particular,
                                               without alteration or
                                               enlargement, or any change
                                               whatever.

                                       4Employment Agreement

 
EXHIBIT 10.1

 
EMPLOYMENT AGREEMENT 
 
THIS EMPLOYMENT AGREEMENT (the “Agreement”), made as
of this 6th day of February, 2003, is entered into by Bio-Imaging Technologies, Inc., a Delaware corporation (the
“Company”), and Ted Kaminer (the “Employee”). 
 
The Company desires to employ the Employee, and the Employee desires to be employed by the Company. In consideration of the mutual covenants and promises contained in this Agreement, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged by the parties to this Agreement, the parties agree as follows: 
 
1. Term of Employment. The Company hereby agrees to employ the Employee, and the Employee hereby accepts employment with the Company, upon the
terms set forth in this Agreement, for the period commencing on February 24, 2003 (the “Commencement Date”) and ending on February 24, 2004 (such period, as it may be extended, the “Employment Period”), unless sooner
terminated in accordance with the provisions of Section 4; provided, however, that the Employment Period shall automatically renew for successive 12 month terms unless either party provides the notice of termination set forth in
Section 4.5 below. 
 
2. Title; Capacity. The Employee shall
serve as Senior Vice President and Chief Financial Officer or in such other reasonably comparable position as the Company or its Board of Directors (the “Board”) may determine from time to time. The Employee shall be based at the
Company’s headquarters in Newtown, Pennsylvania, or such place or places in the continental United States as the Board shall reasonably determine. The Employee shall be subject to the supervision of, and shall have such authority as is
delegated to the Employee by, the Board, President or Chief Executive Officer of the Company. 
 
The Employee hereby accepts such employment and agrees to undertake the duties and responsibilities inherent in such position and such other duties and responsibilities as the Board or its designee
shall from time to time reasonably assign to the Employee. The Employee agrees to devote his entire business time, attention and energies to the business and interests of the Company during the Employment Period; provided, that, the Employee may
serve as a non-executive director or trustee of other companies or entities so long as such service does not unreasonably interfere with the Employee’s duties hereunder. The Employee agrees to abide by the rules, regulations, instructions,
personnel practices and policies of the Company and any changes therein which may be adopted from time to time by the Company. The Employee further agrees to abide by the applicable rules, practices, policies, restrictions and principles outlined by
the Board in its Corporate Policy Governance Manual and amendments adopted thereto. 
 
3. Compensation and Benefits. 
 
3.1 Salary. The Company shall pay the Employee, in periodic installments in accordance with the Company’s customary payroll practices, an annual base salary of $175,000 for the one-year period commencing on the
Commencement Date. 

 
3.2 Fringe Benefits.
The Employee shall be entitled to participate in all bonus and benefit programs that the Company establishes and makes available to its senior executives, if any, to the extent that Employee’s position, tenure, salary, age, health and other
qualifications make him eligible to participate. The Employee shall be entitled to four (4) weeks paid vacation per year, to be taken at such times as may be approved by the Chief Executive Officer. 
 
3.3 Reimbursement of Expenses. The Company shall reimburse the Employee
for all reasonable travel, entertainment and other expenses incurred or paid by the Employee in connection with, or related to, the performance of his duties, responsibilities or services under this Agreement, in accordance with policies and
procedures, and subject to limitations, adopted by the Company or the Board from time to time. 
 
3.4 Bonuses; Incentive Compensation. Beginning in fiscal 2003, the Employee shall be eligible to receive an annual bonus (the “MIP Bonus”) up to a maximum amount equal to 40% of the
Employee’s annual base salary upon the achievement of certain milestones as set forth in an annual Management Incentive Plan. The specific annual milestones will be set each year by the Compensation Committee of the Board of Directors.

 
3.5 Stock Options. You will be granted an option to
purchase up to 100,000 shares of Common Stock of the Company at a purchase price equal to 100% of the fair market value of the Common Stock on the date of the grant, which options will vest as follows: 25% shall vest on the Commencement Date, and
25% per annum shall vest on a monthly basis (i.e. 2,083.33 shares per month) from the Commencement Date. 
 
4. Termination of Employment Period. The employment of the Employee by the Company pursuant to this Agreement shall terminate upon the occurrence of any of the following: 
 
4.1 Expiration of the Employment Period; 
 
4.2 At the election of the Company, for Cause (as defined below), immediately
upon written notice by the Company to the Employee, which notice shall identify the Cause upon which the termination is based. For the purposes of this Section 4.2, “Cause” shall mean that (i) the Employee has repeatedly failed to perform
his assigned duties for the Company after 10 days written notice and an opportunity to cure, (ii) the Employee has engaged in dishonesty, gross negligence or misconduct materially detrimental to the Company’s interest, or (iii) the conviction
of the Employee of, or the entry of a pleading of guilty or nolo contendere by the Employee to, any crime involving moral turpitude or any felony; 
 
4.3 At the election of the Employee, for Good Reason (as defined below), immediately upon written notice by the Employee to the Company, which notice
shall identify the Good Reason upon which the termination is based. For the purposes of this Section 4.3, “Good Reason” for termination shall mean (i) a material adverse change in the Employee’s authority, duties or compensation
without the prior written consent of the Employee, (ii) a material breach by the Company of the terms of this Agreement, which breach is not remedied by the Company within 10 days following written notice from the Employee to the Company notifying
it of such breach or (iii) the relocation of the Employee’s place of work more than 50 miles from the Company’s current executive offices; 
 

2 

 
4.4 Upon the death or
disability of the Employee. As used in this Agreement, the term “disability” shall mean the inability of the Employee, due to a physical or mental disability, for a period of 90 days, whether or not consecutive, during any 360-day period,
to perform the services contemplated under this Agreement, with or without reasonable accommodation as that term is defined under state or federal law. A determination of disability shall be made by a physician satisfactory to both the Employee and
the Company; provided, that, if the Employee and the Company do not agree on a physician, the Employee and the Company shall each select a physician and these two together shall select a third physician, whose determination as to
disability shall be binding on all parties; or 
 
4.5 At the
election of either party, upon not less than 180 days’ prior written notice of termination (the “Termination Notice Period”); provided, however, that if the Company pays the Severance Amount (as defined below) set forth
in Section 5.1(b) below, then the Termination Notice Period shall automatically end on the date the Severance Period (as defined below) begins. 
 
5. Effect of Termination. 
 
5.1 Payments Upon Termination. 
 
(a) In the event the Employee’s employment is terminated pursuant to Section 4.1, Section 4.2, and Section 4.4 or by
the Employee pursuant to Section 4.5, the Company shall pay to the Employee the compensation and benefits otherwise payable to him under Section 3 through the last day of his actual employment by the Company. 
 
(b) In the event the Employee’s
employment is terminated by the Employee pursuant to Section 4.3 or by the Company pursuant to Section 4.5, the Company shall continue to pay to the Employee his salary as in effect on the date of termination and continue to provide to the Employee
the other benefits owed to him under Section 3.2 (to the extent such benefits can be provided to non-employees, or to the extent such benefits cannot be provided to non-employees, then the cash equivalent thereof) until the date 180 days (the
“Severance Period”) after the date of termination (the “Severance Amount”), and the Company shall pay to the Employee the pro-rated amounts due under Section 3.4 and Employee’s options shall continue to vest during the
Severance Period as proscribed under Section 3.5. Such Severance Amount shall be paid over the Severance Period in accordance with the Company’s normal payment practices. Such Severance Period shall immediately terminate (and payments made
pursuant to this Section 5.1(b) shall cease) if the Employee fails to be reasonably cooperative, responsive or available for reasonable requests by the Company to the Employee to assist the Company pertaining to areas of the Company’s business
that the Employee is familiar with as a result of his employment. The payment to the Employee of the amounts payable under this Section 5.1(b) shall constitute the sole remedy of the Employee in the event of a termination of the Employee’s
employment in the circumstances set forth in this Section 5.1(b). The Employee shall not be entitled to any payments under this Section 5.1(b) unless and until the Employee executes a mutual general release and waiver in a form reasonably
satisfactory to the Board. 
 

3 

 
(c) Change in Control. (i) In the event that there shall be a Change in Control (as defined below) of the Company or in any person directly or indirectly presently controlling the Company, as defined in paragraph (ii) below,
all options to purchase shares of Common Stock of the Company shall vest and become immediately exercisable by the Employee for a period of not less than one year after the date of such Change in Control. 
 
(ii) For purposes of this Agreement, a Change
in Control of the Company, or in any person directly or indirectly controlling the Company, shall mean: 
 
(A) A Change in Control as such term is presently defined in Regulation 240.12b-2 under the Securities Exchange Act of
1934, as amended (the “Exchange Act); or 
 
(B) If any “person” (as such term is used in Section 13(d) and 14(d) of the Exchange Act) other than the Company or any “person” who on the date of this Agreement is a director or officer of the Company, becomes
the “beneficial owner” (as defined in Rule 13(d)-3 under the Exchange Act), directly or indirectly, of securities of the Company representing at least fifty (50%) percent of the voting power of the Company’s then outstanding
securities, unless such person becomes such a beneficial owner as a result of a transaction approved by a majority of the board of directors of the Company; or 
 
(C) If during the term of this Agreement, individuals who at the beginning of such period
constitute the Board of Directors cease for any reason to constitute at least a majority thereof, unless the election of each director who is not a director at the beginning of such period has been approved in advance by directors representing at
least a majority of the directors then in office who were directors at the beginning of the period. 
 
5.2 Survival. The provisions of Sections 5.1(b), 5.1(c) and 6 shall survive the termination of this Agreement. 
 
6. Non-Competition and Non-Solicitation. The Employee shall execute, if not previously executed and still in effect,
simultaneously with the execution of this Agreement, or otherwise upon the request of the Company, the Company’s customary form of Non-Competition and Non-Solicitation Agreement and form of Invention Assignment and Confidential Information
Agreement, substantially in the form attached hereto as Exhibit A and Exhibit B, respectively. 
 
7. Other Agreements. The Employee represents that his performance of all the terms of this Agreement and the performance of his duties as an employee of the Company do not and will not breach
any agreement with any prior employer or other party to which the Employee is a party (including without limitation any nondisclosure or non-competition agreement). Any agreement to which the Employee is a party relating to nondisclosure,
non-competition or non-solicitation of employees or customers is listed on Schedule A attached hereto. 
 

4 

 
8. Miscellaneous.

 
8.1 Notices. Any notices delivered under this Agreement
shall be deemed duly delivered four business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent for next-business day delivery via a reputable nationwide overnight
courier service, in each case to the address of the recipient set forth on the signature page hereto. Either party may change the address to which notices are to be delivered by giving notice of such change to the other party in the manner set forth
in this Section 8.1. 
 
8.2 Pronouns. Whenever the context
may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 
 
8.3 Entire Agreement. This Agreement constitutes the entire agreement
between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. 
 
8.4 Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Employee. 
 
8.5 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the Commonwealth of Pennsylvania (without reference to the conflicts of laws provisions thereof). Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall be commenced
only in a court of the Commonwealth of Pennsylvania (or, if appropriate, a federal court located within Pennsylvania), and the Company and the Employee each consents to the jurisdiction of such a court. The Company and the Employee each hereby
irrevocably waive any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement. 
 
8.6 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and
assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company’s assets or business; provided, however, that the obligations of the Employee are personal and shall not
be assigned by him. Notwithstanding the foregoing, if the Company is merged with or into a third party which is engaged in multiple lines of business, or if a third party engaged in multiple lines of business succeeds to the Company’s assets or
business, then for purposes of this Agreement, the term “Company” shall mean and refer to the business of the Company as it existed immediately prior to such event and as it subsequently develops and not to the third party’s other
businesses. 
 
8.7 Waivers. No delay or omission by the
Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or
waiver of any right on any other occasion. 
 
8.8 Captions.
The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. 
 

5 

 
8.9 Severability. In
case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 
 
[Signature Page Follows] 
 

6 

 
THE EMPLOYEE
ACKNOWLEDGES THAT HE HAS CAREFULLY READ THIS AGREEMENT, HAS HAD A FULL OPPORTUNITY TO REVIEW THIS AGREEMENT AND CONSULT WITH COUNSEL AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT. 
 
IN WITNESS WHEREOF, the parties hereto have executed this
Agreement as of the day and year set forth above. 
 

	 BIO-IMAGING TECHNOLOGIES, INC.

	
	 By:
	 	 /s/    Mark L. Weinstein        

Name: Mark L. Weinstein 
Title: President & CEO 
Address: 826 Newtown-Yardley Road  
Newtown, Pennsylvania 18940 
 

	
	 EMPLOYEE

	
	 /s/    Ted Kaminer        

	 Ted Kaminer

	 12 Chateau Drive
Cherry Hill, NJ 08003

 
 

	

 
 
 
 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]